High-grade glioma before and after treatment with radiation and Avastin: Initial observations

被引:63
作者
Fischer, Ingeborg [1 ]
Cunliffe, Clare H. [1 ]
Bollo, Robert J. [2 ]
Raza, Shahzad [5 ]
Monoky, David [3 ]
Chiriboga, Luis [1 ]
Parker, Erik C. [2 ]
Golfinos, John G. [2 ]
Kelly, Patrick J. [2 ]
Knopp, Edmond A. [3 ]
Gruber, Michael L. [4 ]
Zagzag, David [1 ]
Narayana, Ashwatha [5 ]
机构
[1] NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA
[2] NYU, Med Ctr, Dept Neurosurg, New York, NY 10016 USA
[3] NYU, Med Ctr, Dept Radiol, New York, NY 10016 USA
[4] NYU, Med Ctr, Dept Oncol, New York, NY 10016 USA
[5] NYU, Med Ctr, Dept Radiat Oncol, New York, NY 10016 USA
关键词
angiogenesis; Avastin; bevacizumab; biomarkers; glioblastoma; glioma;
D O I
10.1215/15228517-2008-042
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We evaluate the effects of adjuvant treatment with the angiogenesis inhibitor Avastin (bevacizumab) on pathological tissue specimens of high-grade glioma. Tissue from five patients before and after treatment with Avastin was subjected to histological evaluation and compared to four control cases of glioma before and after similar treatment protocols not including bevacizumab. Clinical and radiographic data were reviewed. Histological analysis focused on microvessel density and vascular morphology, and expression patterns of vascular endothelial growth factor-A (VEGF-A) and the hematopoietic stem cell, mesenchymal, and cell motility markers CD34, smooth muscle actin, D2-40, and fascin. All patients with a decrease in microvessel density had a radiographic response, whereas no response was seen in the patients with increased microvessel density. Vascular morphology showed apparent "normalization" after Avastin treatment in two cases, with thin-walled and evenly distributed vessels. VEGF-A expression in tumor cells was increased in two cases and decreased in three and did not correlate with treatment response. There was a trend toward a relative increase of CD34, smooth muscle actin, D2-40, and fascin immunostaining following treatment with Avastin. Specimens from four patients with recurrent malignant gliomas before and after adjuvant treatment (not including bevacizumab) had features dissimilar from our study cases. We conclude that a change in vascular morphology can be observed following antiangiogenic treatment. There seems to be no correlation between VEGF-A expression and clinical parameters. While the phenomena we describe may not be specific to Avastin, they demonstrate the potential of tissue-based analysis for the discovery of clinically relevant treatment response biomarkers. Neuro-Oncology 10, 700-708, 2008 (Posted to Neuro-Oncology [serial online], Doc. D08-00-006, August 12, 2008. URL http:neuro-oncology.dukejournals.org; DOI: 10.1215/15228517-2008-042)
引用
收藏
页码:700 / 708
页数:9
相关论文
共 39 条
[1]   Roles of fascin in cell adhesion and motility [J].
Adams, JC .
CURRENT OPINION IN CELL BIOLOGY, 2004, 16 (05) :590-596
[2]   Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins:: Evidence for distinct angiogenic subtypes [J].
Birner, P ;
Piribauer, M ;
Fischer, I ;
Gatterbauer, B ;
Marosi, C ;
Ambros, PF ;
Ambros, IM ;
Bredel, M ;
Oberhuber, G ;
Rössler, K ;
Budka, H ;
Harris, AL ;
Hainfellner, JA .
BRAIN PATHOLOGY, 2003, 13 (02) :133-143
[3]   The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies [J].
Blümcke, I ;
Giencke, K ;
Wardelmann, E ;
Beyenburg, S ;
Kral, T ;
Sarioglu, N ;
Pietsch, T ;
Wolf, HK ;
Schramm, J ;
Elger, CE ;
Wiestler, OD .
ACTA NEUROPATHOLOGICA, 1999, 97 (05) :481-490
[4]  
Blümcke I, 1999, MICROSC RES TECHNIQ, V46, P53
[5]   Medulloblastoma simulating acute myeloid leukemia: Case report with a review of "myeloid antigen" expression in nonhematopoietic tissues and tumors [J].
Etzell, Joan E. ;
Keet, Corinne ;
McDonald, William ;
Banerjee, Anuradha .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2006, 28 (11) :703-710
[6]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400
[7]   Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy [J].
Ferrara, N ;
Hillan, KJ ;
Novotny, W .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) :328-335
[8]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[9]   VEGF as a therapeutic target in cancer [J].
Ferrara, N .
ONCOLOGY, 2005, 69 :11-16
[10]   Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle-like cells and form vascular networks in vivo [J].
Ferreira, Lino S. ;
Gerecht, Sharon ;
Shieh, Hester F. ;
Watson, Nicki ;
Rupnick, Maria A. ;
Dallabrida, Susan M. ;
Vunjak-Novakovic, Gordana ;
Langer, Robert .
CIRCULATION RESEARCH, 2007, 101 (03) :286-294